A clinical study of NC 650
Latest Information Update: 19 Nov 2024
Price :
$35 *
At a glance
- Drugs NC 605 (Primary)
- Indications Osteogenesis imperfecta
- Focus Adverse reactions
- 19 Nov 2024 New trial record
- 07 Nov 2024 According to a NextCure media release, company plans to start IND filings within 12 to 18 months if financial support from third parties is secured.